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Abstract
Neuroendocrine (NE) prostate cancer (PCa) is a highly aggressive subtype of prostate can-
cer associated with resistance to androgen ablation therapy. In this study, we used LNCaP
prostate cancer cells cultured in a serum-freemedium for 6 days as a NE model of prostate
cancer. Serumdeprivation increased the expression of NEmarkers such as neuron-specific
enolase (NSE) and βIII tubulin (βIII tub) and decreased the expression of the androgen
receptor protein in LNCaP cells. Using cDNAmicroarrays, we compared gene expression
profiles of NE cells and non-differentiated LNCaP cells. We identified up-regulation of 155
genes, among them LAMP2, a lysosomal membrane protein involved in lysosomal stability
and autophagy. We then confirmedup-regulation of LAMP2 in NE cells by qRT-PCR, West-
ern blot and confocal microscopy assays, showing that mRNA up-regulation correlatedwith
increased levels of LAMP2 protein. Subsequently, we determinedautophagy activity in NE
cells by assessing the protein levels of SQSTM/p62 and LC3 by Western blot and LC3 and
Atg5mRNAs content by qRT-PCR. The decreased levels of SQSTM/p62was accompanied
by an enhanced expression of LC3 and ATG5, suggesting activation of autophagy in NE
cells. Blockage of autophagy with 1μMAKT inhibitor IV, or by silencing Beclin 1 and Atg5,
prevented NE cell differentiation, as revealed by decreased levels of the NEmarkers. In
addition, AKT inhibitor IV as well as Beclin1 and Atg5 kwockdown attenuated LAMP2
expression in NE cells. On the other hand, LAMP2 knockdown by siRNA led to a marked
blockage of autophagy, prevention of NE differentiation and decrease of cell survival.
Taken together, these results suggest that LAMP2 overexpression assists NE differentia-
tion of LNCaP cells induced by serum deprivation and facilitates autophagy activity in order
to attain the NE phenotype and cell survival. LAMP2 could thus be a potential biomarker
and potential target for NE prostate cancer.
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Introduction
Prostate cancer is the secondmost common cancer in men, with an estimated 1.1 million cases
diagnosedworldwide in 2012 (GLOBOCAN2012) [1]. Prostate cancer represents an important
public health problem throughout the world and for developed countries in particular, since
almost 70% of the cases (759,000) occur in more developed regions. Prostate tumors initially
depend on androgens. Thus, androgen deprivation therapy (ADT) is used to treat advanced
prostate and yields transient efficacy. This therapy consists in administrating LHRH agonists
or antagonist which prevent the secretion of the pituitary hormone LH which, in turn, reduces
the production of androgens by the testicles [2]. In addition, patients can also receive antian-
drogen treatment to block the effects of adrenal residual androgens, this strategy has been
termed “combined androgen blockage” [3–5]. Unfortunately, ADT has limited and transient
efficacy and most patients receiving it progress to a more aggressive form of the disease termed
castration-resistant prostate cancer (CRPC) [5, 6]. The mechanism by which resistance occurs
has not been completely elucidated and thus represents a major clinical problem. There is evi-
dence of androgen receptor (AR) reactivation despite decreased serum levels of androgens as
an adaptive survival response [4].
One of the hallmarks of advanced prostate cancer is the acquisition of a neuroendocrine
phenotype. Neuroendocrine differentiation (NED) is recognized as an adaptation response
mechanism to hormonal therapy and represents an aggressive variant of prostate cancer [7, 8].
The amount of NED in prostate adenocarcinoma increases with disease progression and its
incidence is expected to increase due to the use of new potent androgen signaling inhibitors in
clinical practice [9]. Peptides produced by neuroendocrine (NE) cells, such us neuron-specific
enolase (NSE) and chromogranin A, have been detected in the serumof advanced and CRPC
patients [10–12]. How NE cells contribute to prostate cancer progression is yet unresolved.
These cells are non-mitotic but secrete different neuropeptides and growth factors which could
contribute to maintain homeostasis of surrounding cell populations [13]. NED is a highly het-
erogeneous phenomenon that points to poor prognosis [14, 15]. The origin of NE tumor cells
has been hypothesized to arise by transdifferentiation from exocrine tumor cells since NE and
exocrine tumor cells from radical prostatectomies share identical allelic profiles [16].
In vitro, prostate adenocarcinoma cells have the capacity to transdifferentiate to a neuroen-
docrine phenotype by exposure to stimuli such as dibutyryl-cyclicAMP [17, 18], forskolin and
IL-6 [19], VIP [20] or hormone-depletedmedium [21]. The LNCaP cell line is widely used as a
cellular model to study the biology of NE transdifferentiation. In this study, we have used
LNCaP cells to determine the gene expression profile in NED by performing genome-wide
transcriptomic analysis. Our results show up-regulated expression of lysosome-associated
membrane glycoprotein 2 (LAMP2) in NE-differentiated LNCaP cells.
LAMP2 is a single-span lysosomal membrane protein which maintains lysosomal stability
and participates in autophagy [22]. Structurally, it consists of a polypeptide core of approxi-
mately 44 kDa with a short cytoplasmic tail (Ct), a transmembrane domain, and a large luminal
domain with extensive N-glycosylation and some O-glycosylation (Nt) which forms a nearly
continuous coat on the inner surface of the lysosomal membrane, protecting it from lysosomal
proteolitic enzyme hydrolysis [23]. Apart from its role in maintaining the structural integrity
of the lysosomal membranes, LAMP2 is critical for lysosomal function [24]. Mice lacking
LAMP2 accumulate autophagic vacuoles in several tissues [25]. In humans, mutations in the
LAMP2 gene cause Danon disease, an X-linked lysosomal storage disorder characterized by
accumulation of vacuolar compartments in heart and skeletal muscle, leading to cardiomyopa-
thy and myopathy [26, 27]. Three spliced variants of the LAMP2 gene generated by alternative
splicing have been described: LAMP-2A, LAMP-2B and LAMP-2C, which differ in the
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transmembrane and cytoplasmic domains [28]. LAMP-2A functions as a receptor of chaper-
one-mediated autophagy (CMA), a lysosomal proteolytic process known to be activated during
starvation that removes damaged cellular proteins [29]; LAMP-2B is more abundantly
expressed in muscle and brain and its absence is associated with Danon disease development;
the LAMP-2C isoform functions as a receptor for RNA and DNA degradation [30, 31].
Macroautophagy (here referred to as autophagy) has emerged as a way to elude cancer ther-
apy and to promote tumor progression [32, 33]. Prostate cancer treatments such as ADT, tax-
ane and kinase inhibitors usually induce autophagy conferring resistance of prostate cancer
cells to therapy. Therefore pharmacological inhibition of autophagy in combination with cur-
rent prostate cancer therapies or chemotherapy drugs has been proposed as an alternative to
improve prostate cancer treatments [34]. The aim of this study was to analyze the role of
LAMP2 up-regulation in neuroendocrinedifferentiation of LNCaP cells and its relationship
with autophagy.
Materials andMethods
Materials
Bafilomycin A1 and 3-methyladenine (3-MA) were from Sigma (St. Louis, MO, USA).
LY294002 was from Tocris (Bristol, UK) and Akt inhibitor IV was purchased from Calbiochem
(Darmstadt, Germany). Primary antibodies used in this study were: monoclonal anti-NSE
fromDAKO (Glostrup, Denmark), monoclonal anti-LAMP2 from Abcam (Cambridge, UK),
anti-p62, anti-pAkt, anti-Atg5 and anti-GAPDH from Cell Signalling Technology (Danvers,
MA, USA), anti-Beclin 1 was from ThermoFisher Scientific (Alcobendas, Spain), polyclonal
anti-LC3 fromNovus (Abingdon, England, UK) and polyclonal anti-βIII tubulin from Cov-
ance (Princeton, NJ, USA). The secondary antibodies were: peroxidase labeled anti-mouse IgG
from Sigma (St. Louis,MO, USA) and anti-rabbit IgG from Calbiochem (Darmstadt,
Germany).
Cell culture
The human prostate carcinoma cell line LNCaP was purchased from American Type Culture
Collection (ATCC CRL-1740) (Rockville,MD, USA). Cells were used at passages 3 to 20 and
routinely grown in complete medium consisting in RPMI 1640 medium containing phenol red
and supplemented with 100 IU/ml penicillinG sodium, 100 μg/ml streptomycin sulfate,
0.25 μg/ml amphotericin B (Invitrogen, Paisley, UK) and 10% foetal calf serum.To elicit neuro-
endocrine differentiation, LNCaP cells were cultured as follows: cells were seeded at a density
of 10,000 cells/cm2 in complete medium. After 48 hours, the mediumwas replaced by serum-
free medium (SF) and the cells were continuously cultured for 2 to 6 days without splitting.
Cells seeded at the same density and cultured at the same time in a complete mediumwere
used as a control. Most of the experiments were carried out with LNCaP cells cultured for 6
days in complete medium (C cells) or in SF medium (NE cells).
DNAmicroarray and differential gene expression analysis
Genome-wide transcriptomic analysis was performed using the whole human genome oligo
microarray from Agilent platform GPL4133. Total RNA was isolated from LNCaP cells cul-
tured in serum-freemedium for 4 hours or 6 days using Trizol reagent according to the manu-
facturer’s recommended protocol. RNA labeling, hybridization and washing were carried out
following Agilent's instructions. Images of hybridizedmicroarrays were acquired with a DNA
microarray scanner. Data were background corrected and normalized using the quantile
LAMP2Up-Regulation in Neuroendocrine ProstateCancer
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method (Bolstadt et al., 2003). Differential expression analysis was assessed using the linear
modeling features of the Limma package from Bioconductor open source software (http://
www.bioconductor.org/. DNA microarray assays and bioinformatic data analyses were carried
out in the Genomics Unit of the Spanish National Center for Cardiovascular Research (CNIC,
Madrid, Spain). Results from differential expression analysis were further analyzed for func-
tional enrichment by using GSEA (Gene Set Enrichment Analysis) v2.2.2 software [35] an
open source tool from the Broad Institute (http://software.broadinstitute.org/gsea/index.jsp).
Gene OntologyMolecular Process, Cellular Components and Molecular Function gene sets
(GO:MP, GO:CC and GO:MF) were downloaded from the Broad Institute’s Molecular Signa-
ture Database (version 4.0).
Western blotting
After treatments, cells were lysed in a lysis buffer (50 mM Tris pH 7.4, 0.8 M NaCl, 5 mM
MgCl2, 0.1% Triton X-100) containing protease inhibitor and phosphatase inhibitor cocktails
(Roche Diagnostics;Mannheim, Germany) and then cleared by microcentrifugation.Total
protein content was measured by the BioRadTM protein assay kit (Bio-Rad Laboratories, Rich-
mond, CA, USA) and 20 μg of protein were separated by electrophoresis on 15%–8% sodium
dodecyl sulfate polyacrylamide gels. Proteins were transferred onto an Immobilon PVDF
membrane (Bio-Rad Laboratories, Richmond, CA, USA) at 100 V for 2 hours at 4°C.Mem-
branes were incubated with the indicated primary antibodies overnight at 4°C and then with
the respective secondary antibody. Visualization was performed by incubating the membrane
for 3 min with enhanced chemo luminescence detection buffer (100 mMTris-HCl pH 8.5, 1.25
mM luminol, 0.2 mM p-coumaric acid, and 0.03% H2O2 and exposed to an Curix RP2 Plus X-
ray film (AGFA, Mortsel, Belgium).Densitometric analysis of the blot bands was performed by
using Scion Image software (Scion Corporation, Informer Technologies, Inc). GAPDH was
used as an internal control. For each blot, fold change in a protein expression level is calculated
by dividing the density of each experimental condition by that from control sample. For each
protein, data are expressed as the mean of the fold change and standard deviation obtained
from at least three independent experiments.
Confocal microscopy
Cells were grown on glass coverslips and at the end of incubation periodwere fixed in 4% para-
formaldehyde in PBS and incubated with 0.1% Triton X-100 for permeabilization. Immunola-
beling with primary antibody was performed by incubation at room temperature for 1h.
Secondary labeling was performedwith Alexa Flour 594, conjugated to anti-rabbit IgG and
Alexa Flour 488 (Invitrogen). Coverslips were then mounted on slides with DAPI-containing
mounting medium. Lysosomes were stained by loading cells with 50 nM lysotracker red (Life
Technologies, Thermo Fisher Scientific,Waltham, MA USA) for 1 h before the end of the
experiment. The cells were then fixed and permeabilized as described above. Imaging was per-
formed with a Leica TCS SP5 laser-scanning confocal microscopewith LAS-AF imaging soft-
ware, using a 63X oil objective. Quantification of the confocal images was performed by using
ImageJ v1.46 software (NIH Image) with co-localization analysis plugins for the quantitative
co-localization study (Wright Cell Imaging Facility).
RT-qPCR
RNA extractionwas carried out using the Trizol reagent (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s recommended protocol. Two μg of total
RNA were reverse transcribedwith Transcriptor Reverse Transcriptase (Roche Applied
LAMP2Up-Regulation in Neuroendocrine ProstateCancer
PLOSONE | DOI:10.1371/journal.pone.0162977 September 14, 2016 4 / 24
Science,Mannheim, Germany). Real-time quantitative PCR was performed to amplify between
25 and 100 ng of cDNA using the following pairs of primers: human NSE sense 5´-GGCTAC
ACGGAAAAGATCGTTATT-3´ and antisense 5´-GAAGGATCAGTGGGAGACTTGAA-3´;
human LAMP2 sense 5´-TGCTGGCTACCATGGGGCTG-3´ and antisense 5´-GCAGCTGC
CTGTGGAGTGAGT-3´; ATG sense5´-CAACTTGTTTCACGCTATATCAGG-3´ and anti-
sense 5´-CACTTTGTCAGTTACCAA CGTCA-3´, human LC3 sense5´-TGTCCGACTTATT
CGAGAGCAGCA-3´ and antisense 5´-TTCACCAACAGGAAGAAGGCCTGA-3´, human
18S sense5´-GTAACCCGTTGAACCCCATT-3´ and antisense 5´-CCATCCAATCGGTAG
TAGCG3´ on the7500 FAST Real Time PCR System (Applied Biosystems) with SYBR Green
(Applied Biosystems, Foster City, USA). Target gene expression was normalized to 18S levels
in respective samples as an internal control.
siRNA
Cells were transfected in Opti-MEM1 I Reduced SerumMedium (Gibco, Thermo Fisher Sci-
entific) containing 4 μg Lipofectamine1RNAiMAX (Invitrogen, ThermoFisher Scientific)
with 100 nM of specific siRNA or control scrambled duplex for 12 h according to the manufac-
turer’s protocols. The sequences of siRNAs used in this study were: LAMP2 5´-GCUGUGCG
GUCUUAUGCAUdTdT-3’ and ATG5: 5’-GUGAGAUAUGGUUUGAAUAdTdT-3’ (Invitro-
gen, ThermoFisher Scientific,Alcobendas, Spain). For Beclin1 specific Silent Select siRNA was
used (Ambion, ThermoFisher Scientific, Alcobendas, Spain). Then the mediumwas removed
and replaced by RPMI containing 10% FBS (control) or serum-freemedium (NE) and cultured
for 72 h. Afterwards, the cells were transfected a second time using the same conditions and
maintained in culture for an additional 72 h. At the end of the incubation, the cells were used
for western blot or cell viability assays.
Cell viability assay
For cell viability assays cells were seeded in a 12-well plate at a 50,000 cells per well and main-
tained for 48 h. Then the mediumwas changed for another mediumwithout antibiotic and
with or without 10% fetal bovine serum, cells were transfected with the corresponding siRNA
and maintained in culture for 6 days. Cell viability was assayed by colorimetricMTT assay.
Statistical Analysis
All statistical analyze of the microarray data was carried out using R (Smyth GH 2005) in the
Genomics Unit of the Spanish National Center for Cardiovascular Research (CNIC,Madrid,
Spain). For the rest of the analyses, data are presented as the mean ± S.D. of at least three sepa-
rate experiments. Statistical significance between groups was tested by Student’s two-tailed and
paired t-test using Instat software (Graphad SofwareStat Software, San Diego, CA, USA). Dif-
ferences among groups were considered significant when P<0.05 or P<0.01 as indicated.
Results
Serumdeprivation induces neuroendocrinedifferentiation of LNCaP
cells
LNCaP cells underwent neuroendocrine (NE) differentiation by serum deprivation of culture
medium for 6 days (hereafter calledNE cells). βIII Tubulin (βIII Tub) and neuron-specific eno-
lase (NSE) levels were assessed as NE markers. Serumdepletion increased the protein levels of
βIII Tub and NSE in LNCaP cells in a time-dependentmanner (S1 Fig), reaching maximum
values at 6 days of serum deprivation. Therefore, LNCaP cells cultured in serum-freemedium
LAMP2Up-Regulation in Neuroendocrine ProstateCancer
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for 6 days were chosen for the rest of the studies as a NE differentiationmodel. In accordance
with previous reports showing a reduced expression and /or activity of AR [36], NE cells
showed a decreasedAR expression besides to increasedNE markers (Fig 1A). We then assessed
the levels of NSE mRNA in NE and control cells by qRT-PCR (Fig 1B) and verified that
increased protein levels of NSE correlated with enhanced levels of NSE mRNA in NE cells. In
addition, and according to previously reports [18], we corroborated that the neuroendocrine
phenotype of LNCaP cells is reversible since the levels of NE markers rise when SF medium is
replaced with a complete medium and cells are maintained in culture for an additional 6 days
(Fig 1C).
Differential gene expression in neuroendocrinedifferentiated LNCaP
cells
In order to determine the gene expression profile of NE cells and the differentially expressed
genes (DEGs) in NE cells versus control cells, we used cDNA microarray technology. From
15,450 genes analyzed in the microarray, 404 of them were differentially expressed in NE cells
versus control cells. Among them, 155 genes were up-regulated and 249 genes were down-reg-
ulated in NE cells. The list of DEGs in NE cells is shown in supplemental data (S1 and S2
Tables). The analysis of differentially expressed genes corroborated the up-regulation of the
NSE gene in NE cells. The functional analysis of DEGs using GSEA v2.2.2 software identified
four categories of Biological Process (GO:BP) enrichment in NE cells. The enriched genes of
“Anatomical_Structure_Development” and “Signal_Transduction” are shown in supplemental
data (S2 Fig and S3 Table). Signal transduction enrichment was due to 22 DEGs from which
interleukin 1β (IL1β) and a glutamate ionotrophic receptor kainate type (GRIK1) were the
most over expressed genes in NE cells, and cyclin A2 (CCNA2), topoisomerase 2A (TOP2A)
and neuromedin U (NMU) were the most down regulated genes in these cells (S2 Fig and S3
Table). By contrast, the categoryMolecular Function (GO:MF) did not result in any outcome;
whereas the Cellular Component (GO:CC) category identified an enrichment in membrane
components (“Intrinsic_To_Membrane” and “Integral_To_Membrane” ) (Fig 2 and Table 1).
Membrane component enrichment was due to 31 DEGs genes (Fig 2), from which 19 genes
were up-regulated in NE cells (Table 1). Among the up-regulated genes, we detected high
expression of the lysosomal-associatedmembrane protein 2 (LAMP2), a membrane glycopro-
tein specific for late endosomes and lysosomes [37] which has been reported to be critical for
lysosomal stability and lysosomal degradation of autophagic vacuoles [22, 38].
Confirmationof LAMP2 up regulation in neuroendocrinedifferentiated
LNCaP cells
To validate the observedLAMP2 up-regulation in NE cells, we assessed LAMP2 protein
expression by western blot and mRNA expression by quantitative RT-PCR, showing that NE
cells overexpressed both LAMP2 protein and mRNA (Fig 3A and 3B). LAMP2 was observed as
a completely glycosylatedmature form (*110 kDa) and less glycosylated form (< 110 kDa).
Overexpression of LAMP2 in NE cells was then further evaluated by immunofluorescence
analysis. Confocalmicroscopy and quantitative analysis of confocal images showed a signifi-
cantly increase of LAMP2 immunoreactivity in NE cells (Fig 3C). LAMP2 accumulated perinu-
clearly as well as at the edge and at the extensions of NE cells. Since LAMP2 is a membrane
protein present in lysosomes, we used lysotracker, an acid-dependent dye, to determine co-
localization of LAMP2 and these acidic subcellular compartments (Fig 3D). Lysotracker stain-
ing quantification demonstrated increased fluorescence in NE cells suggesting an increase in
lysosomes as well as other acidic structures during the NE differentiation process. Moreover,
LAMP2Up-Regulation in Neuroendocrine ProstateCancer
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the quantitative analysis of double-fluorescence staining revealed partial co-localization of
LAMP2 and such acidic structures. In spite of both LAMP2 and lysotracker fluorescence are
Fig 1. Serumwithdrawal induces reversible neuroendocrine differentiationof LNCaP cells. (A) LNCaP cells cultured in
serum-containingmedium (C, control cells) or in serum-freemedium (NE, neuroendocrine cells) during 6 days were lysed and
neuron-specific enolase (NSE), βIII tubulin (βIII Tub) and androgen receptor (AR) were measured in whole lysates by western blot.
GAPDHwas used as a loading control. Densitometric analysis of theWestern blot bands are shown on the right. (B)Quantification
of neuron-specific enolase (NSE)mRNA in control and NE cells by real time qRT-PCR. (C) LNCaP cells were grown in serum-
containing medium (C, control cells), serum-free medium (NE* cells) during 12 days or serum-free medium for the first 6 days and
then themediumwas replaced by a serum-containingmediumand cells were cultured for another 6 days (NE+FBS). Thereafter,
cells were lysed and neuron-specific enolase (NSE) and βIII tubulin (βIII Tub) were measured in whole lysates by Western blot.
GAPDHwas used as a loading control. Densitometric analysis of theWestern blot bands are shown on the right. Results are the
mean ± S.D. of at least three independent experiments (* p<0.05 and ** p<0.01 versus control cells and # p<0.05 versus
neuroendocrine cells, compared by the Student’s t test).
doi:10.1371/journal.pone.0162977.g001
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notably increased in NE cells, quantitative analysis of co-localization showed a similar extent of
co-localization in control and NE cells. On the other hand, LAMP2 expression in plasma mem-
branes has been detected in blood and tumor cells [39, 40] and we cannot rule out increased
expression of LAMP2 in NE cells plasma membrane.
Autophagy is activated in neuroendocrinedifferentiated LNCaP cells
The elevated expression of LAMP2 in NE cells along with the previous knowledge of the critical
role of LAMP2 for the fusion of autophagic vacuoles with lysosomes [25] suggested that neuro-
endocrine differentiationmight activate autophagy in LNCaP cells. To explore the status of
Fig 2. Heatmap showing enrichment inmembranecomponents from DEGs between NE and control
cells.DEGs betweenNE and control cells were functionally assessed using GSEA. GeneOntology gene
sets were downloaded from the Broad Institute’s Molecular SignatureDatabase (version 4.0). Enrichmenton
gene set “intrinsic _to_membrane” is shown. Up-regulated (red) and down-regulated (blue) genes in NE and
control cells are shown.
doi:10.1371/journal.pone.0162977.g002
Table 1. List of genes included in the gene set "Intrinsic_to_membrane" that are UP- or DOWN-regulated in neuroendocrine cells. FC*: Fold
change.
Symbol Gene ID Gene NAME FC*
CPE 1363 carboxypeptidase E 3,97
GPA33 10223 glycoprotein A33 (transmembrane) 3,42
GRB10 2887 growth factor receptor-bound protein 10 4,12
GRIK1 2897 glutamate receptor, ionotropic, kainate 1 13,86
LAMP2 3920 lysosomal-associatedmembrane protein 2 3,31
MAN1C1 57134 mannosidase, alpha, class 1C, member 1 3,06
MDGA1 266727 MAM domain containing glycosylphosphatidylinositol anchor 1 4,72
MME 4311 membranemetallo-endopeptidase 3,61
MPP1 4354 membrane protein, palmitoylated 1, 55kDa 5,31
NBEA 26960 neurobeachin 3,82
NCAM2 4685 neural cell adhesionmolecule 2 3,18
NLGN1 22871 neuroligin 1 3,58
OPRK1 4986 opioid receptor, kappa 1 9,90
PLEKHB1 58473 pleckstrin homology domain containing, family B (evectins) member 1 3,74
RHCE 6006 Rh blood group, CcEe antigens 3,01
ROR2 4920 receptor tyrosine kinase-like orphan receptor 2 3,74
SLC12A2 6558 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 3,24
SORL1 6653 sortilin-related receptor, L(DLR class) A repeats-containing 3,60
TRPC1 7220 transient receptor potential cation channel, subfamily C, member 1 3,33
ATAD5 79915 ATPase family, AAA domain containing 5 - 2,68
BCL2L13 23786 BCL2-like 13 (apoptosis facilitator) - 2,66
BDKRB1 623 bradykinin receptor B1 - 3,87
CENPE 1062 centromere protein E, 312kDa - 15,75
EIF5A 1984 eukaryotic translation initiation factor 5A - 3,18
LMNB1 4001 lamin B1 - 8,29
SEC22C 9117 SEC22 vesicle trafficking protein homologC (S. cerevisiae) - 2,80
SSH1 54434 slingshot homolog 1 (Drosophila) - 3,18
TM4SF1 4071 transmembrane 4 L six family member 1 - 15,42
TMEM48 55706 transmembrane protein 48 - 5,63
TMPO 7112 thymopoietin - 3,99
doi:10.1371/journal.pone.0162977.t001
LAMP2Up-Regulation in Neuroendocrine ProstateCancer
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autophagy in NE cells, we determined the protein levels of microtubule-associated protein 1
light chain 3 (LC3) by western blot. During autophagy, the LC3 precursor is cleaved at its C-
terminus to form a truncated cytosolic form named LC3-I. LC3-I is then conjugated with
phosphatidylethanolamine and bound to the autophagosome membrane to form LC3-II.
Therefore, LC3-II levels could be used as an autophagosome accumulationmarker. However,
as autophagy is a dynamic process, increased levels of LC3-II could also reflect a reduction in
autophagosome turnover or even induction of autophagy with impaired turnover ability. To
distinguish such situations, LC3-II should be detected in the absence and in the presence of
inhibitor of lysosome activity such as lysosomal proteases E64 and pepstatin A or bafilomycin
A1, which prevents LC3-II turnover by inhibiting lysosomal proteolitic activity and, in the case
of bafilomycin A1, autophagosome-lysosome fusion [41]. Autophagosome turnover can also be
determined by measurement of the adaptor protein sequestosome 1 (SQSTM1/p62), a protein
that recruits ubiquitinated proteins to autophagosomes and whose levels inversely correlate
with activation of autophagy [41, 42]. NE cells showed an increase in LC3-II and a decrease in
p62 levels compared with control LNCaP cells, and such variations were detectedwhen E64
and pepstatin A or 100 nM bafilomycin A1 was present in the culture medium during the last
three hours (S3 Fig and Fig 4A), suggesting an induction of autophagic flux in NE cells.
To corroborate autophagy activation in NE cells, we labeled endogenous LC3 by immuno-
fluorescence (Fig 4B). Confocalmicroscopy images showed diffuse cytoplasmic staining of LC3
in control cells and a punctuate LC3 pattern in NE cells, and as expected such switch was nota-
bly stronger when bafilomycin A1 was present. Quantitative analysis of confocal images
revealed a significant increase of LC3 immunostaining in NE cells corroborating western blot-
ting results. It should be note that bafilomycin A1 treatment exerted a significantly lower accu-
mulation of LC3 immunostaining in control than in NE cells, suggesting that autophagic flux is
greater in NE cells than in control cells.
Although the transcriptional regulation of autophagy has not been closely correlated with
functional autophagy, new studies propose a post-transcriptional regulation at the level of gene
expression, particularly in long-term autophagic response and in genes involved in the later
stages of autophagy [43]. Using qRT-PCR, we determined the mRNA levels of the ATG5 and
LC3 genes, which are required for phagophore expansion and autophagosome formation,
respectively (Fig 4C). We detected enhanced levels of ATG5 and LC3 mRNA suggesting up-
regulated expression of both genes in NE cells. In the case of LC3, increasedmRNA levels cor-
relate with greater protein content, suggesting that transcriptional inductionmay be necessary
to replenish the LC3 protein that is turned over during autophagy flux activation.
Autophagy inhibition prevents neuroendocrinedifferentiation of LNCaP
cells
To assess the role of autophagy activity on neuroendocrinedifferentiation of LNCaP cells, we
silenced Beclin1, an autophagy gene which interacts with class III PI3K to initiate autophago-
some formation, and Atg5, which form part of the complex Atg5-Atg12/Atg16L involved in
Fig 3. Lysosomal-associatedmembrane protein 2 (LAMP2) is over-expressed in neuroendocrine differentiated
LNCaP cells. LNCaP cells were grown in serum-containingmedium (C, control cells) or serum-freemedium (NE,
neuroendocrine cells) during 6 days. (A) LAMP2was measured in whole lysates of C and NE cells by western blot along with
neuroendocrinemarkers neuron-specific enolase (NSE) and βIII tubulin (βIII Tub). GAPDHwas used as a loading control.
Densitometric analysis of theWestern blot bands are shown on the right. (B)Quantification of LAMP2mRNA in control and
NE cells by real time qRT-PCR. Results are themean ± S.D. of at least three independent experiments (* p<0.05 versus
control cells compared by the Student’s t test). (C)Detection of LAMP2 by immunofluorescence (green). Nuclei are stained
with DAPI (blue). Immunofluorescencewas analyzed by confocal microscopy. Quantitative analysis of lysotracker and
LAMP2was performed using ImageJ software (NIH).
doi:10.1371/journal.pone.0162977.g003
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LC3 lipidation (Fig 5). Loss of expression of Beclin 1 and Atg5 was verified by Western blot-
ting. Next, we evaluated autophagy activity by measuring LC3 and p62 protein levels. Beclin1
and Atg5 silencing resulted in accumulation of p62 protein in both control and NE cells, dem-
onstrating an efficient blockage of autophagy. In the case of LC3 levels, we observed that
Beclin1 and Atg5 knockdown exerted opposite effect, while Beclin1 knockdown decreased
LC3I protein levels, Atg5 elicited notably accumulation of LC3I in both control and NE cells.
Regarding NEmarkers, Beclin 1 and Atg5 knockdown significantly reduced NSE protein levels
in NE cells and, in a less extent, those of βIII tub. Taken together, those results clearly demon-
strate that autophagy activity supports NED of LNCaP cells.
LAMP2 knockdown prevents autophagy, neuroendocrinedifferentiation
and survival of LNCaP cells
To answer the question of whether LAMP2 up-regulation is required to induce NED and
autophagy in LNCaP cells, LAMP2 was knocked down in control and NE cells by interference
RNA. Loss of expression of LAMP2 in cells transfected with siLAMP2 was verified by Western
blotting (Fig 6A). Silencing of LAMP2 in NE cells significantly decreased the levels of the neu-
roendocrinemarker βIII Tub but not those of NSE. Autophagy activity was evaluated by mea-
suring p62 levels in whole lysates. siLAMP2 resulted in an accumulation of the cargo protein
p62 in both control and NE cells, indicating that knocking down of LAMP2 blocks the fusion
of autophagosomes and lysosomes, as has been previously reported [25]. In addition, LAMP2
knockdown significantly reduced cell viability of both control and NE LNCaP cells (Fig 6B).
These findings strongly support a role of LAMP2 on autophagy activity as well as on survival
and NED of LNCaP cells.
Autophagy inhibition decreases LAMP2 levels and survival of
neuroendocrinedifferentiated LNCaP cells
Next, we determine whether autophagy activity play a role in regulating LAMP2 expression.
We examine LAMP2 protein levels in Beclin1 and Atg5 silenced control and NE LNCaP cells
(Fig 7A). Blockage of autophagy by knocking down Beclin1 or Atg5 significantly decrease
LAMP2 protein levels in NE cells. A similar effect was also observed in control LNCaP cells.
Since LAMP2 knockdown elicited a dramatic decrease in cell survival, we examine cell viability
in Beclin1 and Atg5 silenced cells (Fig 7B). Beclin1 knockdown significantly decreased survival
of both control and NE cell, whether such effect is related with diminished levels of LC3
observed in Beclin 1 silenced cells (Fig 5) should be further analyzed. In contrast, Atg5 knock-
down had no effect on viability of control LNCaP cells but significantly decreased cell survival
of NE cells. These results demonstrated that autophagy activity contributes to regulates
LAMP2 protein level and NE cells survival.
Fig 4. Autophagy is activated in neuroendocrine differentiatedLNCaP cells. LNCaP cells were grown in serum
containing medium (C, control cells) or serum-free medium (NE, neuroendocrine cells) during 6 days, and when indicated
100 nMBafilomycin A1 was added to the culturemedium for the last three hours. (A)Autophagy activationmarkers, LC3 and
p62, along with neuroendocrinemarkers NSE and βIII Tub were measured in whole lysates of C and NE cells by Western
blot. GAPDHwas used as a loading control. Densitometric analysis of theWestern blot bands are shown on the right. (B)
Detection of LC3 protein by immunofluorescence (green) and nuclei with DAPI (blue). Immunofluorescencewas analyzed by
confocal microscopy. Quantitative analysis of LC3 was performedusing ImageJ software (NIH). (C)Quantification of LC3
and Atg5mRNA in control and NE cells by real time qRT-PCR. Results are themean ± S.D. of at least three independent
experiments (* p<0.05 and ** p<0.01 versus control cells and # p<0.05 versus neuroendocrine cells, compared by the
Student’s t test).
doi:10.1371/journal.pone.0162977.g004
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Fig 5. Autophagy blocking prevents neuroendocrine differentiation of LNCaP cells. LNCaP cells grown in serum-containing
medium (C, control cells) or serum-free medium (NE, neuroendocrine cells) were transfected with negative control siRNA (siC) or
siRNA targetingBeclin1 (siBeclin1) or siRNA targetingAtg5 (siATG5) during 6 days. Thereafter, cells were lysed and Beclin1 or
Atg5, autophagymarkers, LC3 and p62, and neuroendocrinemarkers, NSE and βIII Tub were measured in whole lysates by
Western blot. GAPDHwas used as a loading control. Densitometric analysis of theWestern blot bands are shown on the right.
Results are themean ± S.D. of at least three independent experiments (*p<0.05 and **p<0.01 versus non-treated control cells and
# p<0.05 versus non-treatedneuroendocrine cells, compared by the Student’s t test).
doi:10.1371/journal.pone.0162977.g005
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Inhibition of AKT blocks autophagy and prevents overexpression of
LAMP2 and neuroendocrinedifferentiation of LNCaP cells
We and others have reported the importance of the PI3K/AKT/mTOR pathway for NE differ-
entiation [20, 44, 45]. In addition, we have very recently demonstrated that serum deprivation
Fig 6. LAMP2 knockdown prevents autophagy, neuroendocrine differentiation and survival of LNCaP cells. LNCaP cells
were transfected with negative control siRNA (siC) or siRNA targeting LAMP2 (siLAMP2) and grown in serum-containingmedium
(C, control cells) or serum-free medium (NE, neuroendocrine cells) during 6 days. (A)Cells were lysed and LAMP2, autophagy
markers, LC3 and p62, and neuroendocrinemarkers, NSE and βIII Tub, were measured in whole lysates by Western blot.
GAPDHwas used as a loading control. Densitometric analysis of theWestern blot bands are shown on the right. (B)Cell viability
of control and NE cells treatedwith siC or siLAMP2was monitoredby MTT assay. Results are themean ± S.D. of at least three
independent experiments (* p<0.05 and ** p<0.01 versus siC transfected control cells and # p<0.05 and ## p<0.01 versus siC
transfected neuroendocrine cells, compared by the Student’s t test).
doi:10.1371/journal.pone.0162977.g006
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of LNCaP cells increases AKT phosphorylation at Ser473 as well as the phosphorylation of its
downstream signaling protein S6, which correlates with the increase in NE markers expression
Fig 7. Autophagy inhibitiondecreaseLAMP2 levels and survival of neuroendocrine differentiated LNCaP
cells. LNCaP cells were transfected with negative control siRNA (siC) or siRNA targetingBeclin1 (siBeclin1) or si
RNA targetingAtg5 (SiATG5) and grown in serumcontaining medium (C, control cells) or serum-freemedium
(NE, neuroendocrine cells) during 6 days. (A)Cells were lysed and Beclin1 (left), Atg5 (right) and LAMP2were
measured in whole lysates by Western blot. GAPDHwas used as a loading control. Densitometric analysis of the
Western blot bands are shown below. (B)Cell viability of control and NE cells treatedwith siC, siBeclin1 (left) or
SiATG5 (right)was monitoredby MTT assay. Results are the mean ± S.D. of three independent experiments (*
p<0.05 versus siC transfected control cells and # p<0.05 and ## p<0.01 versus siC transfected neuroendocrine
cells, compared by the Student’s t test).
doi:10.1371/journal.pone.0162977.g007
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[46]. Here, and to gain a deeper understanding of the relationship between LAMP2, autophagy
and NE differentiation of LNCaP cells, we investigated the effect of the pharmacological inhibi-
tion of AKT on autophagy, LAMP2 and NE markers expression in LNCaP cells (Fig 8). In
some conditions, cells were treated with Bafilomycin A1 during the last three hours in culture
in order to block autophagy flux for better recover LC3II signal. Treatment of cells with the
selective AKT inhibitor IV resulted in accumulation of the cargo protein p62, and a decrease of
the expression of LAMP2 and NE markers in NE cells, indicating that AKT activity regulates
autophagic flux, LAMP2 expression and neuroendocrinedifferentiation.
Discussion
NED is one of the hallmarks of advanced castration-resistant prostate cancer and has been pro-
posed as a mechanism of resistance to current therapies [8]. Using expression microarrays, we
have identified 404 genes differentially expressed betweenNE-differentiated and non-differen-
tiated LNCaP cells. Among them, 155 genes were up-regulated including LAMP2, and 249
genes were down-regulated in NE cells.
LAMP2 plays an important role in lysosomal stability as well as in autophagy. Lysosomes
are cellular compartments that digest and recycle materials and cancer cells are dependent of
effective lysosomal function [47]. A reduction of LAMP2 protein levels triggers lysosomal
membrane permeabilization and sensitizes cells to the lysosomal cell death pathway [48]. Sev-
eral lines of evidence associate enhanced levels of LAMP2 with tumor progression. The major-
ity of cancer cells display LAMP2 expression and, surprisingly, the prostate along with the
thyroid gland are the tissues which show the strongest immunoreativity against LAMP2 (the
human protein atlas; http://www.proteinatlas.org/). In colorectal cancer epithelium, LAMP1
and LAMP2 levels are increased, suggesting that LAMPs are related to neoplastic progression,
but there is no direct association between such up-regulated expression and cell proliferation
[49]. Our results show that in NE cells, LAMP2 is up-regulated, both at the level of mRNA.
This overexpression was accompanied by increased autophagy activity. In addition, knock-
down of LAMP2 hampered NED, as demonstrated by the decreased levels of NE markers, cell
survival and prevented autophagy, as demonstrated by p62 protein accumulation. To our
knowledge, this is the first report showing the involvement of LAMP2 in NE differentiation of
prostate cancer cells. Lysosomes are the terminal degradative compartment for autophagy and
LAMP2 plays a critical role in the fusion of autolysosomes with lysosomes to form the hybrid
structure called autophagolysosome. Reduced fusion has been shown in cells depleted of
LAMP2 as demonstrated in LAMP2 knockout mice which showed accumulation of autophagic
vacuoles in several tissues [25] and in patients with Danon disease [26, 27]. The increased
expression of LAMP2 could help NE cells increase the fusion activity between lysosomes and
autophagosomes, leading to the increased autophagy activity shown in NE cells and constitut-
ing a survival signal for NE cells. In breast tumors, LAMP-2A overexpression leads to CMA
activation and cancer cell survival [50]. Moreover, Kon et al. have been shown overexpression
of LAMP-2A and CMA activation in more than 40 different types of human tumors when
compared with normal tissue surrounding the tumors. In line with this, blockage of CMA
reduces the metastatic capacity of lung cancer cells due to the reduced capacity of tumor cells
to sustain their enhancedmetabolic activity [51]. However, we have not investigated whether
CMAwas enhanced in NE cells. This question will be addressed in future studies.
LAMP2 expression is not exclusive of lysosomal and late endosomalmembranes. It can also
be associated to the cell plasma membrane. Human peripheral bloodmononuclear cells
(PBMC) have been shown to express LAMP2 in their plasma membrane. Moreover, stimula-
tion of PBMC with the lectin phytohaemagglutinin increased LAMP2 levels, a rise which was
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Fig 8. Pharmacological inhibition of AKT prevents autophagy, LAMP2overexpression and
neuroendocrine differentiationof LNCaP cells. LNCaP cells were grown in serum-containingmedium (C,
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involved in PBMC adhesion to vascular endothelium [39]. More recently, Damaghi et al. have
shown LAMP2 overexpression in plasma membranes of MCF-7 breast cancer cell line, adapted
to grow in acidic conditions, both in vitro and in vivo [40]. They extended their studies to
breast cancer patients and showed enhanced levels of LAMP2 in breast cancer tumors as com-
pared to normal tissue. This increase correlated with increased tumor progression. The authors
explain the overexpression of LAMP2 as an adaptation mechanism to chronic acidosis in the
tumor microenvironment, since depletion of LAMP2 is sufficient to increase acidosis-mediated
toxicity and, interestingly, tap-water bicarbonate sodium therapy reduces LAMP2 expression.
They propose the use of LAMP2 as a marker to quantify the presence of acidity in biopsies of
solid tumors as well as a novel therapeutic target [40]. It is important to note that in TRAMP
mice, an animal model of prostate cancer that displays NE differentiation, systemic sodium
bicarbonate buffer administration inhibits carcinogenesis [52]. It will be interesting to investi-
gate the expression levels of LAMP2 in tumors of this prostate cancer animal model to eluci-
date its possible role in tumor progression, and extend these studies to other NE prostate
cancer models such as xenografts.
Macroautophagy (here referred to autophagy) has emerged as a way to elude cancer therapy
and to promote tumor progression [32, 33]. Prostate cancer treatments such as ADT, taxane
and kinase inhibitors usually induce autophagy conferring resistance of the prostate cancer
cells to therapy. Hence, pharmacological inhibition of autophagy in combination with current
prostate cancer therapies or chemotherapy drugsmay improve prostate cancer treatments
[34]. Here, we show significant increase of ATG5 and LC3 mRNA levels as assessed by
qRT-PCR that correlates with increased levels of LC3 protein and elevated autophagy flux, as
assessed by decreased levels of p62 in NE cells. In addition, the pharmacological and molecular
inhibition of autophagy, besides blocking autophagy flux, prevents NE differentiation of
LNCaP cells, as shown by decreased levels of NE markers as well as cell survival. These results
demonstrate that autophagy activation is required for survival and NE differentiation of
LNCaP cells. The importance of PI3K/AKT/mTOR pathway on autophagy regulation is well
established [53]. During starvation,mTOR is inhibited allowing autophagy to be activated. Sur-
prisingly, here we observed that autophagy is activated in NE cells along with PI3K/AKT/
mTOR activation, maybe because, as has been previously described [54], in prolonged starva-
tion systems mTOR reactivation is required for the degradation of autolysosomes. We cannot
discard such possibility in our model of NED since serum-starvation lasts for 6 days. On the
other hand, Matsuda-Lennikov et al. have recently demonstrated that accumulation of AKT at
the lysosomal membrane is critical for autophagy induction [55]. It seems that spatial control
of AKT determines autophagy activity, thus AKT targeted to plasma membrane via class I
PI3K production of PtdIns(3,4,5)P3 inhibits autophagy, while AKT targeted the lysosome via
class III PI3K generation of PtdIns(3)P promotes autophagy [55, 56]. We showed that AKT
inhibition disrupts autophagy and NE differentiation of LNCaP cells, however we not known
AKT subcellular localization. Accordingly with our results, Fan et al. reported that AKT and
autophagy cooperate to promote survival of drug-resistance glioma [57].
control cells) or serum-free medium (NE, neuroendocrine cells) during 6 days. Cells where treatedwith
vehicle (vhc) or 1 μMAKT inhibitor IV for 6 days. When indicated, cells were treatedwith 100 nM bafilomycin
A1 for the last three hours in culture. Thereafter cells were lysed and autophagymarkers, LC3 and p62,
LAMP2 and neuroendocrine markers, NSE and βIII Tub, were measured in whole lysates by Western blot.
GAPDHwas used as a loading control. Densitometric analysis of theWestern blot bands are shown on the
right. Results are the mean ± S.D. of at least three independent experiments (* p<0.05 and **p<0.01 versus
not treated control cells and # p<0.05 versus not treated neuroendocrine cells, compared by the Student’s t
test).
doi:10.1371/journal.pone.0162977.g008
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Autophagy activation is also reported in NE differentiation induced by IL-6 treatment of
LNCaP, conferring resistance to etoposide treatment [58]. IL-6 treatment down-regulates the
expression of REST (repressor element-1 silencing transcription factor) [58, 59], a neuronal
transcriptional repressor known to be down-regulated in neuroendocrineprostate cancer [60],
and the decreased levels of REST allow LNCaP cells to activate autophagy [58]. In our model of
NED, we did not observe changes in the expression of REST, suggesting that the driving force
to achieve the NE phenotype is quite different in IL-6-treated and serum-starvedLNCaP cells.
In our model, we have demonstrated that serum-deprivation induction of NE marker expres-
sion is correlated with increasedAKT activity and decreasedAMPK activity and that the can-
nabinoidWIN 55,212–2 inhibits PI3K/AKT, resulting in AMPK activation and prevention of
NED [46]. In this study, we extend these results showing that the induction of autophagy by
serum starvation is dependent on AKT activity since AKT inhibitor IV blocks autophagy and
prevents overexpression of both LAMP2 and NE markers. A role of autophagy in protein traf-
ficking and secretion pathway has been proposed [61, 62], so the activation of autophagy and
LAMP2 overexpression observed in our model of NED could be related with the secretory
activity of neuroendocrine cells.
In summary, we describe, for the first time, the up-regulation of LAMP2 as a survival signal
for NE differentiation of LNCaP cells induced by serum deprivation during 6 days. LAMP2
could thus be a molecular component of NE differentiation and could be used as a NE marker.
Further studies are warranted in order to gain a better understanding of the complex NE differ-
entiation process.
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